Metraipolis › archive › dc_b16fa105ea86
Efficacy and safety of almonertinib as adjuvant therapy in stage II-IIIA EGFR-mutant non-small cell lung cancer: a retrospective study — Europe PMC PMID:42625890
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42625890
- DOI
- 10.3389/fmed.2026.1891244
- License (as archived)
- solo-consultazione
- Archived
- 2026-10-17T01:20:37.550Z
- SHA-256 of the archived text
f104a73156e3f7d9c3aeb897268165f6dcb8bebb3a0bbbfab0f87867344c0eff- Stable URL of this page
https://metraipolis.com/documento/dc_b16fa105ea86
How to cite
Efficacy and safety of almonertinib as adjuvant therapy in stage II-IIIA EGFR-mutant non-small cell lung cancer: a retrospective study — Europe PMC PMID:42625890 — Europe PMC (en), https://europepmc.org/article/MED/42625890 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_b16fa105ea86 (Metraipolis archive dc_b16fa105ea86, sha256 f104a73156e3f7d9c3aeb897268165f6dcb8bebb3a0bbbfab0f87867344c0eff)
BibTeX
@misc{dcb16fa105ea86,
title = {Efficacy and safety of almonertinib as adjuvant therapy in stage II-IIIA EGFR-mutant non-small cell lung cancer: a retrospective study — Europe PMC PMID:42625890},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42625890},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_b16fa105ea86; sha256 f104a73156e3f7d9c3aeb897268165f6dcb8bebb3a0bbbfab0f87867344c0eff},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42625890. Agents can read the archived copy with the MCP tool read_document.